Key result
Streptozocin-induced diabetic cardiomyopathy reduces rat LVEF ~24%, driven by circMAP3K5-mediated apoptosis.
Why the study?
Diabetic cardiomyopathy lacks effective treatments and the regulatory role of circMAP3K5 in DCM is largely unclear.
Population
DCM rat hearts and high glucose-induced H9c2 cardiomyocytes
Comparison
circMAP3K5 depletion vs high glucose-induced cardiomyocyte apoptosis
Design
Microarray analysis and mechanistic cellular study
Authors
Loading...
Should not yet alter clinical management; hypothesis-generating for circMAP3K5 targeting in diabetic cardiomyopathy models.
Absolute Event Rate: 56.33% vs 74.06%
p-value: p=0.0005
Shen et al. (2023) studied Diabetic cardiomyopathy (n=20). Streptozocin-induced type 1 diabetes mellitus vs. Normal control was evaluated on Left ventricular ejection fraction (LVEF) (p=0.0005). Streptozocin-induced diabetic cardiomyopathy in rats reduced left ventricular ejection fraction from 74.06% to 56.33%, a pathological process mechanistically driven by circMAP3K5-mediated apoptosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: